MFN2 and Parkinson disease: Our experimental design followed a logical progression of “in vivo preliminary observation-in vitro mechanism exploration-in vivo validation.” Starting with PD model mice, we first observed abnormal motor/cognitive and altered expression of key molecules such as MFN2.